Stevens DL, Dotter B, Madaras-Kelly K (2004) A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2(1):51–59

Article  CAS  PubMed  Google Scholar 

Linezolid injection drug label information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d05541c6-fd63-cc99-e053-2995a90a4ec7#. Accessed 10 May 2023

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605

Article  PubMed  Google Scholar 

National Heart, Lung and Blood Institute. Quality assessment tool for case series studies. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed on 19 Aug 2023

Jonathan Sterne JH, Reeves B, Savovi´c J, Turner L. RoB 2 for crossover trials. https://www.riskofbias.info/welcome/rob-2-0-tool/rob-2-for-crossover-trials. Accessed on 21 Aug 2023

Sisson TL, Jungbluth GL, Hopkins NK (1999) A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol 39(12):1277–1282

Article  CAS  PubMed  Google Scholar 

Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK (2001) Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol 41(5):563–572

Article  CAS  PubMed  Google Scholar 

Grunder G, Zysset-Aschmann Y, Vollenweider F, Maier T, Krähenbühl S, Drewe J (2006) Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers. Antimicrob Agents Chemother 50(1):68–72

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoyo I, Martínez-Pastor J, Garcia-Ramiro S, Climent C, Brunet M, Cuesta M, Mensa J, Soriano A (2012) Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis 44(7):548–550

Article  CAS  PubMed  Google Scholar 

Cojutti P, Maximova N, Crichiutti G, Isola M, Pea F (2015) Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother 70(1):198–206

Article  CAS  PubMed  Google Scholar 

Blassmann U, Roehr AC, Frey OR, Koeberer A, Briegel J, Huge V, Vetter-Kerkhoff C (2016) Decreased linezolid serum concentrations in three critically ill patients: clinical case studies of a potential drug interaction between linezolid and rifampicin. Pharmacology 98(1–2):51–55

Article  CAS  PubMed  Google Scholar 

Pai MP, Cojutti PG, Gerussi V, Della Siega P, Tascini C, Pea F (2022) Linezolid population pharmacokinetics to improve dosing in cardiosurgical patients: factoring a new drug-drug interaction pathway. Clin Infect Dis 25:ciac917

Google Scholar 

Abdelgawad N, Wasserman S, Abdelwahab MT, Davis A, Stek C, Wiesner L, Black J, Meintjes G, Wilkinson RJ, Denti P (2023) Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis. J Infect Dis 22:jiad413

Google Scholar 

Bock M, Van Hasselt JGC, Schwartz F, Wang H, Høiby N, Fuursted K, Ihlemann N, Gill S, Christiansen U, Bruun NE, Elming H, Povlsen JA, Køber L, Høfsten DE, Fosbøl EL, Pries-Heje MM, Christensen JJ, Rosenvinge FS, Torp-Pedersen C, Helweg-Larsen J, Tønder N, Iversen K, Bundgaard H, Moser C (2023) Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis. J Antimicrob Chemother 12:dkad316

Google Scholar 

Gordi T, Tan LH, Hong C et al (2003) The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E. J Clin Pharmacol 43(10):1161–1167

Article  CAS  PubMed  Google Scholar 

Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K (2011) Obach RS. Damle B -J Clin Pharmacol 51(2):229–236

Article  CAS  PubMed  Google Scholar 

Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M (2012) Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67(8):2034–2042

Article  CAS  PubMed  Google Scholar 

Bolhuis MS, van Altena R, van Soolingen D et al (2013) Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 42(6):1614–1621

Article  CAS  PubMed  Google Scholar 

Hashimoto S, Honda K, Fujita K, Miyachi Y, Isoda K, Misaka K, Suga Y, Kato S, Tsuchiya H, Kato Y, Okajima M, Taniguchi T, Shimada T, Sai Y (2018) Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies. J Pharm Health Care Sci 12(4):27

Article  Google Scholar 

Puplà Bartoll A, Bellés Medall MD, Pérez Catalán IE, Roig Martí C, Bodega Azuara J, Gil Candel M, Esteve López V, Ferrando PR (2023) Ajuste posológico de linezolid por interacción con rifampicina en endocarditis infecciosa [Dose adjustment of linezolid due to interaction with rifampicin in infective endocarditis]. Rev Esp Quimioter 36(4):436–438

Article  PubMed  Google Scholar 

Egle H, Trittler R, Kümmerer K, Lemmen SW (2005) Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 77(5):451–453

Article  CAS  PubMed  Google Scholar 

Gebhart BC, Barker BC, Markewitz BA (2007) Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 27(3):476–479

Article  CAS  PubMed  Google Scholar 

Pea F, Furlanut M, Cojutti P et al (2010) Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 54(11):4605–4610

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bolhuis MS, van Altena R, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW (2010) Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 54(12):5418–5419

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pea F, Cadeo B, Cojutti PG, Pecori D, Bassetti M (2014) Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: a case report. Ther Drug Monit 36(5):687–689

Article  PubMed  Google Scholar 

Cojutti P, Crapis M, Bassetti M, Hope W, Pea F (2015) Linezolid underexposure in a patient co-treated with venlafaxine. Eur J Clin Pharmacol 71(10):1285–1286

Article  PubMed  Google Scholar 

Ashizawa N, Tsuji Y, Kawago K, Higashi Y, Tashiro M, Nogami M, Gejo R, Narukawa M, Kimura T, Yamamoto Y (2016) Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring. J Infect Chemother 22(5):331–334

Article  CAS  PubMed  Google Scholar 

Töpper C, Steinbach CL, Dorn C, Kratzer A, Wicha SG, Schleibinger M, Liebchen U, Kees F, Salzberger B, Kees MG (2016) Variable linezolid exposure in intensive care unit patients-possible role of drug-drug interactions. Ther Drug Monit 38(5):573–578

Article  PubMed  Google Scholar 

Yulin Z, Lingti K, Shan G, Yong Z (2020) A possible interaction between linezolid and digoxin: a case report of therapeutic drug monitoring. Saudi Pharm J 28(11):1408–1410

Article  PubMed  PubMed Central  Google Scholar 

Friedrich JO, Adhikari NK, Beyene J (2011) Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. J Clin Epidemiol 64(5):556–564

Article  PubMed  Google Scholar 

Estimating the sample mean and standard deviation (SD) from the five-number summary and its application in meta-analysis. https://www.math.hkbu.edu.hk/~tongt/papers/median2mean.html. Accessed 23 Aug 2023

Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, DʼAvolio A (2019) Different underlying mechanism might explain the absence of a significant difference in area under the concentration-time curve of linezolid for different ABCB1 genotypes. Ther Drug Monit 41(2):254–255

Article  PubMed  Google Scholar 

Siegmund W, Altmannsberger S, Paneitz A, Hecker U, Zschiesche M, Franke G, Meng W, Warzok R, Schroeder E, Sperker B, Terhaag B, Cascorbi I, Kroemer HK (2002) Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther 72(3):256–264

Article  CAS  PubMed  Google Scholar 

Levin GM, Nelson LA, DeVane CL, Preston SL, Eisele G, Carson SW (2001) A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull 35(2):62–71

CAS  PubMed  Google Scholar 

Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, König J, Dörje F, Mürdter TE, Ackermann A, Dormann H, Gassmann KG, Hahn EG, Zierhut S, Brune K, Fromm MF (2007) Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 46(12):1039–1049

Article  CAS  PubMed  Google Scholar 

Fenner KS, Troutman MD, Kempshall S et al (2009) Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85(2):173–181

Article  CAS  PubMed  Google Scholar 

Katoh M, Nakajima M, Yamazaki H, Yokoi T (2001) Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 12(4):505–513

Article  CAS  PubMed  Google Scholar 

Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364(6):551–557

Article  CAS